Literature DB >> 1400564

Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice.

M V Pimm1, S J Gribben.   

Abstract

We have previously shown that Balb/c mice immunised against syngeneic monoclonal antibodies (mAbs), so that they have anti-idiotypic responses against those mAbs, will clear the mAbs from the circulation as a result of immune complex formation. We report here that with three separate mAbs, this clearance of complexes can result in toxicity to the animals. This was particularly severe with one mAb (NCRC-2), in some cases leading to death. It was not seen with Fab/c or Fab fragments of NCRC-2. This toxic response could be passively transferred with serum, indicating that it was due to formation of immune complexes or to their subsequent clearance. Treatment of mice with cobra venom factor, to reduce complement levels, reduced clearance of complexes but had no effect on toxicity. The anti-histamine pyrilamine did not reduce toxicity. This is one of only a few situations in which an anti-(mouse antibody) response has been reported to be potentially dangerous, and is particularly remarkable since it occurs as a result of such a limited anti-antibody response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400564     DOI: 10.1007/bf01209486

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  18 in total

Review 1.  Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases.

Authors:  M J Van Kroonenburgh; E K Pauwels
Journal:  Nucl Med Commun       Date:  1988-11       Impact factor: 1.690

2.  The influence of syngeneic anti-idiotypic antibody on the biodistribution of an anti-tumour monoclonal antibody in BALB/c mice.

Authors:  M V Pimm; L G Durrant; R W Baldwin
Journal:  Int J Cancer       Date:  1989-01-15       Impact factor: 7.396

3.  Chronic serum sickness glomerulonephritis: removal of glomerular antigen and electron-dense deposits is largely dependent on plasma complement.

Authors:  P N Furness; D R Turner
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

4.  Syngeneic anti-idiotypic antibody prevents localization of a murine monoclonal antibody in human tumour xenografts.

Authors:  M V Pimm; R W Baldwin
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

5.  Comparison of biodistribution of 791T/36 monoclonal antibody and its Fab/c fragment in BALB/c mice and nude mice bearing human tumor xenografts.

Authors:  S Demignot; M V Pimm; R W Baldwin
Journal:  Cancer Res       Date:  1990-05-15       Impact factor: 12.701

6.  Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity.

Authors:  J Azuma; T Kurimoto; S Tsuji; N Mochizuki; S Fujinaga; Y Matsumoto; Y Masuho
Journal:  J Immunother (1991)       Date:  1991-08

7.  Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.

Authors:  M S Kaminski; K Kitamura; D G Maloney; R Levy
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

8.  Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEA.

Authors:  M R Price; S Edwards; E Jacobs; I Z Pawluczyk; V S Byers; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Tumour localisation with a radioactively labelled reshaped human monoclonal antibody.

Authors:  V Hird; M Verhoeyen; R A Badley; D Price; D Snook; C Kosmas; C Gooden; A Bamias; C Meares; J P Lavender
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

10.  Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line.

Authors:  M J Embleton; B Gunn; V S Byers; R W Baldwin
Journal:  Br J Cancer       Date:  1981-05       Impact factor: 7.640

View more
  1 in total

Review 1.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?

Authors:  A B Delaloye; B Delaloye
Journal:  Eur J Nucl Med       Date:  1995-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.